<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2019 [PPXK5GW761L0VHER0KNS]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:18pt Times New Roman;margin-top:2.25pt;margin-bottom:0pt'><FONT style=font-size:18pt><B>UNITED STATES</B></FONT></P>
<P align=center style='font:18pt Times New Roman;margin:0'><FONT style=font-size:18pt><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Washington, D.C. 20549 </B></P>
<P style='font:4.5pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:1.5pt'>&#160;</P>
<P align=center style='font:18pt Times New Roman;margin-top:4.5pt;margin-bottom:0pt'><FONT style=font-size:18pt><B>FORM 8-K </B></FONT></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:1.5pt'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>CURRENT REPORT</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d)</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Of the Securities Exchange Act of 1934</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Date of Report (Date of earliest event reported): March 4, 2019</B></P>
<P align=center style='font:20pt Times New Roman;margin-top:18pt;margin-bottom:0pt'><B>MOUNT TAM BIOTECHNOLOGIES, INC. </B></P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P style='font:4.5pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=middle><P style='font:12pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=bottom><P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle><P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>NEVADA</B></FONT></P>
</TD><TD valign=bottom><P align=center style='font:10pt Times New Roman;margin:0'><B>333-192060</B></P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>45-3797537</B></FONT></P>
</TD></TR>
<TR style=height:3.7pt><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(State or other jurisdiction&#160;of</B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:7.5pt><B>incorporation or organization)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Commission File Number)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(I.R.S. Employer</B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:7.5pt><B>Identification Number)</B></FONT></P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>106 Main Street #4E</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='font-size:10pt;border-bottom:1px solid #000000'><B>Burlington, VT 05401</B></FONT><FONT style=font-size:10pt><B> </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>(425) 214-4079</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B> </B></FONT>&nbsp;</P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Address, including zip code, and telephone number, </B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>including area code, of registrant&#8217;s principal executive offices) </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><B>(Former name or former address, if changed since last report)</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt inherit;margin-top:0pt;margin-bottom:10pt;color:#212121;background-color:#FFFFFF'><FONT style='font-family:Times New Roman;color:#000000'>&#160;</FONT>Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>
<P style='font:10pt inherit;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=color:#000000>Emerging growth company &nbsp;&nbsp;</FONT><FONT style='font-family:MS Gothic;color:#000000'>&#9744;</FONT></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:9pt Times New Roman;margin:0'><A name=_iDocIDFieldf8552112-624a-413b-822c-76dc />&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=font-family:inherit>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</FONT><FONT style='font-family:MS Gothic'>&#9744;</FONT></P>
<P style='font:8pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:8pt>&#160; </FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A name=OLE_LINK1 /><FONT style=background-color:#FFFFFF><B>Item 1.01 &nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-50.4pt;margin-left:50.4pt;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-50.4pt;margin-left:50.4pt;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF><B>Item 2.03 &nbsp;&nbsp;&nbsp;Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF><B>Item 3.02 &nbsp;&nbsp;&nbsp;Unregistered Sales of Equity Securities</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><FONT style=color:#212121;background-color:#FFFFFF><I>Convertible Note Transaction with </I></FONT><I>Climate Change Investigation, Innovation and Investment Company, LLC</I></P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>On March 4, 2019, Mount Tam Biotechnologies, Inc. (the &#8220;Company&#8221;), and Climate Change Investigation, Innovation and Investment Company, LLC, a California limited liability company (the &#8220;Lender&#8221;) entered into an arrangement whereby Lender will lend the Company $40,000 pursuant to the terms of a convertible promissory note (the &#8220;Note&#8221;). &#160;The Note bears interest at a rate of 8.0% per annum and has a maturity date of August 31, 2019. &#160;The Manager of Lender, James Farrell, is a director and shareholder of the Company. &nbsp;Pursuant to the requirements of the Nevada Revised Statutes, the disinterested members of the Company&#8217;s board of directors approved the transaction with Lender. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>The Note is secured by that certain Security Agreement dated September 20, 2018 between the Company and the Lender  (included as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on September 26, 2018) (the &#8220;Security Agreement&#8221;) pursuant to which the Company and the Lender agreed that all amounts, liabilities and obligations owed by the Company to the Lender are secured by a security interest in all assets of the Company on the terms and conditions set forth in the Security Agreement.&#160; The security interest granted to the Lender is subject to certain permitted security interests, specifically those interests previously granted to (i) 0851229 BC, Ltd. (&#8220;BC&#8221;) pursuant to an amended and restated security agreement dated as of June 14, 2016 (included as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on June 15, 2016) (the &#8220;BC Security Interest&#8221;) and (ii) Fromar Investments, LP (&#8220;Fromar&#8221;) pursuant to a security agreement dated as of March 5, 2018 (included as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 12, 2018) (the &#8220;Fromar Security Interest&#8221;).</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>Pursuant to the terms of the Note, if the Company issues capital stock or any security convertible into or exercisable for its capital stock in a transaction, the primary purpose of which is to raise capital (a &#8220;Financing&#8221;), the Lender may convert all or any portion of the outstanding principal amount and accrued and unpaid interest into the same securities issued by the Company in the Financing (the &#8220;Financing Securities&#8221;) at a conversion price equal to eighty percent (80%) of the price per Financing Securities paid by the other investors in the Financing. If the Company consummates a Qualified Financing (as hereinafter defined) then the outstanding principal amount and all accrued and unpaid interest shall automatically convert into the same securities issued to investors in the Qualified Financing (the &#8220;Qualified Financing Securities&#8221;) at a conversion price equal to eighty percent (80%) of the price per Qualified Financing Securities paid by the other investors in the Qualified Financing. A &#8220;Qualified Financing&#8221; means a Financing which results in gross proceeds to the Company, in one or a series of related transactions, of at least $2,000,000 (including the aggregate amount of indebtedness converted into equity securities in such Financing), in which either (i) the investor leading negotiations with the Company is a bona fide institutional investor or (ii) the investor leading negotiations with the Company is not a bona fide institutional investor but the Financing includes commercially reasonable customary terms and conditions for an equity financing of an early-stage biopharmaceutical company.</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>Effective upon a complete funding of the entire principal amount of $40,000, the Company agreed to issue to the Lender 80,000 shares of its common stock. &#160;The Company agreed to issue to the Lender an additional 80,000 shares of its common stock in the event that the Company has not either (i) closed a Financing resulting in funding of at least $1,000,000 to the Company after the date of the Note, but on or before August 31, 2019, or (ii) received a binding term sheet or other similar binding agreement pertaining to a licensing transaction with a company that operates in the pharmaceutical and/or biotech industries that will provide for at least $40,000 in upfront payments to the Company on or before August 31, 2019, as well as milestones and royalties for TAM-01, TAM-3, or for any follow-on compounds of the Company (a &#8220;Licensing Transaction&#8221;) on or before August 31, 2019. &#160;The Company agreed to issue to the Lender an additional 60,000 shares of its common stock in the event that the Company has not </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:9pt Times New Roman;margin:0'><A name=_iDocIDFieldfb9f21af-848f-4813-aa3c-475d />&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><FONT style=font-size:10pt>either (i) closed a Financing resulting in funding of at least $1,000,000 to the Company after the date of the Note, but on or before September 30, 2019, or (ii) received a binding term sheet or other similar binding agreement for a Licensing Transaction on or before September 30, 2019.</FONT></P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>The Note and the securities of the Company into which the Note is convertible were offered and sold without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act, and in reliance on similar exemptions under applicable state laws. The Lender has represented to the Company that it is an accredited investor. Proceeds from the loan evidenced by the Note will be used by the Company for working capital purposes. No person received any underwriting discount or commission in connection with the issuance of the securities described herein.</P>
<P style='font:10pt Times New Roman;margin:0;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;background-color:#FFFFFF'><I>First Amendment to Intercreditor Agreement</I></P>
<P style='font:10pt Times New Roman;margin:0;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>In addition to the foregoing, on March 4, 2019 the Company entered into a First Amendment to Intercreditor Agreement (&#8220;Intercreditor Amendment&#8221;) with the Lender, BC and Fromar (collectively, the &#8220;Creditors&#8221;). The Intercreditor Amendment amended that certain Intercreditor Agreement by and among the Company and the Lenders (included as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on September 26, 2018) in order to account for the additional debt owed by the Company to the Lender pursuant to the Note. </P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><A name=co_internalToc_SFSM_1 />&#160;<A name=co_internalToc_FSM_1 />&#160;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>The foregoing descriptions of the Note and the Intercreditor Amendment do not purport to be complete and are qualified in their entirety by the terms and conditions of the agreements themselves. Copies of the Note and the Intercreditor Amendment are attached to this Current Report on Form&#160;8-K as Exhibits 10.1 and 10.2, respectively, and each is incorporated herein by reference.&#160;</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF><B>Item 9.01 Financial Statements and Exhibits.</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A name=co_internalToc_EXL_1 /><FONT style=background-color:#FFFFFF><B>&#160;</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>(d) Exhibits</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<TABLE style=border-collapse:collapse;margin-left:4.65pt><TR style=height:10.8pt><TD valign=middle style='width:63pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>Exhibit No.</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>&#160;</FONT></P>
</TD><TD valign=middle style='width:305pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>Description</FONT></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>10.1</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>&#160;</FONT></P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A href=mntm_ex10z1.htm style=text-decoration:none><FONT style='color:#0000FF;background-color:#FFFFFF;border-bottom:1px solid #0000FF'>Note</FONT></A></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>10.2</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A href=mntm_ex10z2.htm style=text-decoration:none><FONT style='color:#0000FF;background-color:#FFFFFF;border-bottom:1px solid #0000FF'>Intercreditor Amendment</FONT></A></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:9pt Times New Roman;margin:0'><A name=_iDocIDFieldfb9f21af-848f-4813-aa3c-475d />&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SIGNATURES</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>MOUNT TAM BIOTECHNOLOGIES, INC.</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD colspan=2 valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Date:&#160;&#160;&#160;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>March 6, 2019</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>By: </P>
</TD><TD valign=top style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'>/s/ Richard Marshak</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Name: </P>
</TD><TD valign=bottom style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'>Richard Marshak</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Title:</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:9pt Times New Roman;margin:0'><A name=_iDocIDFieldfb9f21af-848f-4813-aa3c-475d />&nbsp;</P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "mntm_8k.htm", "description": "8-K", "secsgml_size_bytes": 23970}]
{"company-data": {"conformed-name": "Mount TAM Biotechnologies, Inc.", "cik": "0001589361", "assigned-sic": "2100", "irs-number": "453797537", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-192060", "film-number": "19665771"}, "business-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945", "phone": "(425) 214-4079"}, "mail-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945"}, "former-company": [{"former-conformed-name": "TabacaleraYsidron, Inc.", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERAYSIDRON INC", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERA YSIDRON INC", "date-changed": "20131016"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2019
MOUNT TAM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA
333-192060
45-3797537
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
106 Main Street #4E
Burlington, VT 05401
(425) 214-4079
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01    Entry into a Material Definitive Agreement
Item 2.03    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02    Unregistered Sales of Equity Securities
Convertible Note Transaction with
Climate Change Investigation, Innovation and Investment Company, LLC
On March 4, 2019, Mount Tam Biotechnologies, Inc. (the "Company"), and Climate Change Investigation, Innovation and Investment Company, LLC, a California limited liability company (the "Lender") entered into an arrangement whereby Lender will lend the Company $40,000 pursuant to the terms of a convertible promissory note (the "Note").  The Note bears interest at a rate of 8.0% per annum and has a maturity date of August 31, 2019.  The Manager of Lender, James Farrell, is a director and shareholder of the Company.  Pursuant to the requirements of the Nevada Revised Statutes, the disinterested members of the Company's board of directors approved the transaction with Lender.
The Note is secured by that certain Security Agreement dated September 20, 2018 between the Company and the Lender  (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on September 26, 2018) (the "Security Agreement") pursuant to which the Company and the Lender agreed that all amounts, liabilities and obligations owed by the Company to the Lender are secured by a security interest in all assets of the Company on the terms and conditions set forth in the Security Agreement.  The security interest granted to the Lender is subject to certain permitted security interests, specifically those interests previously granted to (i) 0851229 BC, Ltd. ("BC") pursuant to an amended and restated security agreement dated as of June 14, 2016 (included as Exhibit 99.2 to the Company's Current Report on Form 8-K filed on June 15, 2016) (the "BC Security Interest") and (ii) Fromar Investments, LP ("Fromar") pursuant to a security agreement dated as of March 5, 2018 (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on April 12, 2018) (the "Fromar Security Interest").
Pursuant to the terms of the Note, if the Company issues capital stock or any security convertible into or exercisable for its capital stock in a transaction, the primary purpose of which is to raise capital (a "Financing"), the Lender may convert all or any portion of the outstanding principal amount and accrued and unpaid interest into the same securities issued by the Company in the Financing (the "Financing Securities") at a conversion price equal to eighty percent (80%) of the price per Financing Securities paid by the other investors in the Financing. If the Company consummates a Qualified Financing (as hereinafter defined) then the outstanding principal amount and all accrued and unpaid interest shall automatically convert into the same securities issued to investors in the Qualified Financing (the "Qualified Financing Securities") at a conversion price equal to eighty percent (80%) of the price per Qualified Financing Securities paid by the other investors in the Qualified Financing. A "Qualified Financing" means a Financing which results in gross proceeds to the Company, in one or a series of related transactions, of at least $2,000,000 (including the aggregate amount of indebtedness converted into equity securities in such Financing), in which either (i) the investor leading negotiations with the Company is a bona fide institutional investor or (ii) the investor leading negotiations with the Company is not a bona fide institutional investor but the Financing includes commercially reasonable customary terms and conditions for an equity financing of an early-stage biopharmaceutical company.
Effective upon a complete funding of the entire principal amount of $40,000, the Company agreed to issue to the Lender 80,000 shares of its common stock.  The Company agreed to issue to the Lender an additional 80,000 shares of its common stock in the event that the Company has not either (i) closed a Financing resulting in funding of at least $1,000,000 to the Company after the date of the Note, but on or before August 31, 2019, or (ii) received a binding term sheet or other similar binding agreement pertaining to a licensing transaction with a company that operates in the pharmaceutical and/or biotech industries that will provide for at least $40,000 in upfront payments to the Company on or before August 31, 2019, as well as milestones and royalties for TAM-01, TAM-3, or for any follow-on compounds of the Company (a "Licensing Transaction") on or before August 31, 2019.  The Company agreed to issue to the Lender an additional 60,000 shares of its common stock in the event that the Company has not
either (i) closed a Financing resulting in funding of at least $1,000,000 to the Company after the date of the Note, but on or before September 30, 2019, or (ii) received a binding term sheet or other similar binding agreement for a Licensing Transaction on or before September 30, 2019.
The Note and the securities of the Company into which the Note is convertible were offered and sold without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act, and in reliance on similar exemptions under applicable state laws. The Lender has represented to the Company that it is an accredited investor. Proceeds from the loan evidenced by the Note will be used by the Company for working capital purposes. No person received any underwriting discount or commission in connection with the issuance of the securities described herein.
First Amendment to Intercreditor Agreement
In addition to the foregoing, on March 4, 2019 the Company entered into a First Amendment to Intercreditor Agreement ("Intercreditor Amendment") with the Lender, BC and Fromar (collectively, the "Creditors"). The Intercreditor Amendment amended that certain Intercreditor Agreement by and among the Company and the Lenders (included as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on September 26, 2018) in order to account for the additional debt owed by the Company to the Lender pursuant to the Note.
The foregoing descriptions of the Note and the Intercreditor Amendment do not purport to be complete and are qualified in their entirety by the terms and conditions of the agreements themselves. Copies of the Note and the Intercreditor Amendment are attached to this Current Report on Form 8-K as Exhibits 10.1 and 10.2, respectively, and each is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
10.1
Note
10.2
Intercreditor Amendment
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOUNT TAM BIOTECHNOLOGIES, INC.
Date:
March 6, 2019
By:
/s/ Richard Marshak
Name:
Richard Marshak
Title:
Chief Executive Officer